282 related articles for article (PubMed ID: 30448640)
21. HIV-1 Vif, APOBEC, and intrinsic immunity.
Goila-Gaur R; Strebel K
Retrovirology; 2008 Jun; 5():51. PubMed ID: 18577210
[TBL] [Abstract][Full Text] [Related]
22. An analog of camptothecin inactive against Topoisomerase I is broadly neutralizing of HIV-1 through inhibition of Vif-dependent APOBEC3G degradation.
Bennett RP; Stewart RA; Hogan PA; Ptak RG; Mankowski MK; Hartman TL; Buckheit RW; Snyder BA; Salter JD; Morales GA; Smith HC
Antiviral Res; 2016 Dec; 136():51-59. PubMed ID: 27825797
[TBL] [Abstract][Full Text] [Related]
23. Identification of an APOBEC3G binding site in human immunodeficiency virus type 1 Vif and inhibitors of Vif-APOBEC3G binding.
Mehle A; Wilson H; Zhang C; Brazier AJ; McPike M; Pery E; Gabuzda D
J Virol; 2007 Dec; 81(23):13235-41. PubMed ID: 17898068
[TBL] [Abstract][Full Text] [Related]
24. APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation. Comparisons with APOBEC3G.
Holmes RK; Koning FA; Bishop KN; Malim MH
J Biol Chem; 2007 Jan; 282(4):2587-95. PubMed ID: 17121840
[TBL] [Abstract][Full Text] [Related]
25. A single amino acid in human APOBEC3F alters susceptibility to HIV-1 Vif.
Albin JS; LaRue RS; Weaver JA; Brown WL; Shindo K; Harjes E; Matsuo H; Harris RS
J Biol Chem; 2010 Dec; 285(52):40785-92. PubMed ID: 20971849
[TBL] [Abstract][Full Text] [Related]
26. Interactions of host APOBEC3 restriction factors with HIV-1 in vivo: implications for therapeutics.
Albin JS; Harris RS
Expert Rev Mol Med; 2010 Jan; 12():e4. PubMed ID: 20096141
[TBL] [Abstract][Full Text] [Related]
27. Differences in APOBEC3G expression in CD4+ T helper lymphocyte subtypes modulate HIV-1 infectivity.
Vetter ML; Johnson ME; Antons AK; Unutmaz D; D'Aquila RT
PLoS Pathog; 2009 Feb; 5(2):e1000292. PubMed ID: 19197360
[TBL] [Abstract][Full Text] [Related]
28. Status of APOBEC3G/F in cells and progeny virions modulated by Vif determines HIV-1 infectivity.
Yamashita T; Nomaguchi M; Miyake A; Uchiyama T; Adachi A
Microbes Infect; 2010 Feb; 12(2):166-71. PubMed ID: 19944180
[TBL] [Abstract][Full Text] [Related]
29. Antiviral roles of APOBEC proteins against HIV-1 and suppression by Vif.
Romani B; Engelbrecht S; Glashoff RH
Arch Virol; 2009; 154(10):1579-88. PubMed ID: 19669862
[TBL] [Abstract][Full Text] [Related]
30. Characterization of conserved motifs in HIV-1 Vif required for APOBEC3G and APOBEC3F interaction.
He Z; Zhang W; Chen G; Xu R; Yu XF
J Mol Biol; 2008 Sep; 381(4):1000-11. PubMed ID: 18619467
[TBL] [Abstract][Full Text] [Related]
31. The Binding Interface between Human APOBEC3F and HIV-1 Vif Elucidated by Genetic and Computational Approaches.
Richards C; Albin JS; Demir Ö; Shaban NM; Luengas EM; Land AM; Anderson BD; Holten JR; Anderson JS; Harki DA; Amaro RE; Harris RS
Cell Rep; 2015 Dec; 13(9):1781-8. PubMed ID: 26628363
[TBL] [Abstract][Full Text] [Related]
32. Long-term restriction by APOBEC3F selects human immunodeficiency virus type 1 variants with restored Vif function.
Albin JS; Haché G; Hultquist JF; Brown WL; Harris RS
J Virol; 2010 Oct; 84(19):10209-19. PubMed ID: 20686027
[TBL] [Abstract][Full Text] [Related]
33. Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F.
Russell RA; Pathak VK
J Virol; 2007 Aug; 81(15):8201-10. PubMed ID: 17522216
[TBL] [Abstract][Full Text] [Related]
34. Human and rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H demonstrate a conserved capacity to restrict Vif-deficient HIV-1.
Hultquist JF; Lengyel JA; Refsland EW; LaRue RS; Lackey L; Brown WL; Harris RS
J Virol; 2011 Nov; 85(21):11220-34. PubMed ID: 21835787
[TBL] [Abstract][Full Text] [Related]
35. Partially active HIV-1 Vif alleles facilitate viral escape from specific antiretrovirals.
Fourati S; Malet I; Binka M; Boukobza S; Wirden M; Sayon S; Simon A; Katlama C; Simon V; Calvez V; Marcelin AG
AIDS; 2010 Sep; 24(15):2313-21. PubMed ID: 20729708
[TBL] [Abstract][Full Text] [Related]
36. APOBEC3-mediated editing in HIV type 1 from pediatric patients and its association with APOBEC3G/CUL5 polymorphisms and Vif variability.
De Maio FA; Rocco CA; Aulicino PC; Bologna R; Mangano A; Sen L
AIDS Res Hum Retroviruses; 2012 Jun; 28(6):619-27. PubMed ID: 22145963
[TBL] [Abstract][Full Text] [Related]
37. Mutational comparison of the single-domained APOBEC3C and double-domained APOBEC3F/G anti-retroviral cytidine deaminases provides insight into their DNA target site specificities.
Langlois MA; Beale RC; Conticello SG; Neuberger MS
Nucleic Acids Res; 2005; 33(6):1913-23. PubMed ID: 15809227
[TBL] [Abstract][Full Text] [Related]
38. Natural polymorphisms in human APOBEC3H and HIV-1 Vif combine in primary T lymphocytes to affect viral G-to-A mutation levels and infectivity.
Refsland EW; Hultquist JF; Luengas EM; Ikeda T; Shaban NM; Law EK; Brown WL; Reilly C; Emerman M; Harris RS
PLoS Genet; 2014 Nov; 10(11):e1004761. PubMed ID: 25411794
[TBL] [Abstract][Full Text] [Related]
39. Comparative analysis of the gene-inactivating potential of retroviral restriction factors APOBEC3F and APOBEC3G.
Bélanger K; Langlois MA
J Gen Virol; 2015 Sep; 96(9):2878-2887. PubMed ID: 26048885
[TBL] [Abstract][Full Text] [Related]
40. High level of APOBEC3F/3G editing in HIV-2 DNA vif and pol sequences from antiretroviral-naive patients.
Bertine M; Charpentier C; Visseaux B; Storto A; Collin G; Larrouy L; Damond F; Matheron S; Brun-Vézinet F; Descamps D;
AIDS; 2015 Apr; 29(7):779-84. PubMed ID: 25985400
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
